Literature DB >> 23935320

Wernicke's encephalopathy and anabolic steroid drug abuse. Is there any possible relation?

P Christopoulos1, C Katsanoulas, G Timplalexi, D Lathyris, S Vasiliagkou, E Antoniadou.   

Abstract

Wernicke's encephalopathy is a reversible, neurologic disorder due to thiamine deficiency which is mainly related to chronic alcohol abuse. We report a case of a young male patient, who was bodybuilder and anabolic drug user, in whom encephalopathy was diagnosed after a short medical course in the ICU after a major upper gastrointestinal bleeding (Mallory-Weiss syndrome) and hypovolemic shock. His clinical condition was typical for Wernicke's encephalopathy and although neuroimaging tests were not indicative, the patient received thiamine supplement therapy, which resulted in rapid clinical improvement. The diagnosis was based only on clinical sings and anabolic drug abuse was considered as a possible predisposing factor for the manifestation of the syndrome.

Entities:  

Keywords:  Wernicke's encephalopathy; anabolic drugs; bodybuilding; oculomotor disturbancies; thiamine deficiency

Year:  2012        PMID: 23935320      PMCID: PMC3738615     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  7 in total

1.  Wernicke encephalopathy: MR findings at clinical presentation in twenty-six alcoholic and nonalcoholic patients.

Authors:  G Zuccoli; M Gallucci; J Capellades; L Regnicolo; B Tumiati; T Cabada Giadás; W Bottari; J Mandrioli; M Bertolini
Journal:  AJNR Am J Neuroradiol       Date:  2007-08       Impact factor: 3.825

Review 2.  Wernicke-Korsakoff syndrome.

Authors:  C Zubaran; J G Fernandes; R Rodnight
Journal:  Postgrad Med J       Date:  1997-01       Impact factor: 2.401

Review 3.  Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management.

Authors:  Gianpietro Sechi; Alessandro Serra
Journal:  Lancet Neurol       Date:  2007-05       Impact factor: 44.182

4.  Neuroprotective strategies in drug abuse-evoked encephalopathy.

Authors:  Ashraf Virmani; Syed F Ali; Zbigniew K Binienda
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

5.  Wernicke encephalopathy: MR findings and clinical presentation.

Authors:  Stefan Weidauer; Michael Nichtweiss; Heinrich Lanfermann; Friedhelm E Zanella
Journal:  Eur Radiol       Date:  2002-09-20       Impact factor: 5.315

6.  Clinical characteristics and MR imaging features of nonalcoholic Wernicke encephalopathy.

Authors:  G-Q Fei; C Zhong; L Jin; J Wang; Yuhao Zhang; X Zheng; Yuwen Zhang; Z Hong
Journal:  AJNR Am J Neuroradiol       Date:  2008-01       Impact factor: 3.825

Review 7.  Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.

Authors:  Jeremy M Wojtowicz; Mark C Yarema; Paul M Wax
Journal:  CJEM       Date:  2008-01       Impact factor: 2.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.